Navigation Links
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
Date:9/17/2009

BRISBANE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

The database, which includes DNA from approximately 1,500 IPF patients, is the largest in the world and offers researchers an opportunity to gain important new insights regarding the pathogenesis of this devastating disease. This announcement comes during the 2009 National Pulmonary Fibrosis (PF) Awareness Week, which is taking place this year September 14 - 21, 2009.

"This is an ideal partnership that will enhance our chances to make breakthroughs in understanding the causes of this disease, the optimal diagnostic strategies and the best prognosticators for patient outcomes," said David Schwartz, MD, the principal investigator of this research.

"We are pleased to be able to partner with National Jewish Health, one of the world's leading institutions in pulmonary medicine, in this important pursuit to better understand the role that genetic factors may play in the development of IPF, a disease that claims approximately 40,000 lives per year," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "With nearly a decade of experience in IPF research and development, we are committed toward advancing care for patients with this uniformly fatal disease who currently hav
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/31/2014)... 2014 2014 Market Research ... professional and in-depth research report on the ... information, including Polyacrylamide definition, classification, application, and ... overview. This research covers the international market ... global industry analysis covering macroeconomic environment & ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... SyntheMed, Inc. ("the Company") (OTCBB: SYMD; Pink Sheets: ... on the treatment of diseases characterized by organ-specific cell damage, ... 2011.  The Company changed its name to "Pathfinder Cell Therapy, ... OTC Bulletin Board, changing to a new trading symbol shortly. ...
... 2011 Omeros Corporation (NASDAQ: OMER ... developing and commercializing products targeting inflammation, coagulopathies and ... that Gregory A. Demopulos, M.D., chairman and chief ... Rodman and Renshaw 13th Annual Healthcare Conference taking ...
... The inaugural  European Neurotech Investing ... It features keynotes on the state of the European neurotech ... presentations on next generation treatments emerging in the EU for ... Alzheimer , s, addiction, depression, schizophrenia, Parkinson ...
Cached Biology Technology:Pathfinder, LLC and SyntheMed, Inc. Complete Merger 2Pathfinder, LLC and SyntheMed, Inc. Complete Merger 3High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 2High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 3
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... rise of the Tibetan plateau -- the largest topographic ... for both its profound effect on climate and its ... GSA Bulletin , Katharine Huntington and colleagues employ ... using modern and fossil snail shells to investigate the ... , Views range widely on the timing of ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... Massey Cancer Center studying the interaction between the ... gamma as one of the signaling proteins involved ... researchers develop tailored vaccines and other immunotherapeutic strategies ... the manipulation of the immune system ?by introducing ...
... M.D. and Ami Klin are part of a global research ... region of a chromosome that may lead to autism in ... Genetics and also will be published in the journal’s March ... scan. Over 120 scientists from over 50 institutions who formed ...
... cause of high blood pressure lies within the brain, and ... by scientists at the University of Bristol, UK, and is ... Waki, working in a research group led by Professor Julian ... (junctional adhesion molecule-1), which is located in the walls of ...
Cached Biology News:Mechanisms involved with tumor relapse identified 2Autism gene identified by researchers at Yale working with a global research consortium 2Blame the brain for high blood pressure 2
... IMPACT (Intein Mediated Purification with an ... activity of engineered protein splicing elements (termed ... single affinity column (1-4) (Figures 1 and ... protein fusion systems by its ability to ...
... all the reagents required for a fast ... activity in cell and tissue extracts and ... has been tested on samples prepared from ... spleen, and heart muscle from several species, ...
... CHEMICON's Skeletal Myogenesis Kit provides ... C2C12 myoblasts into mature skeletal myotubes. ... kit is a valuable tool in ... and in developing strategies for muscle ...
... Detection Assay is an anchorage-independent growth assay ... most stringent assay for detecting malignant transformation ... (pre-treated with carcinogens or carcinogen inhibitors) are ... medium for 21-28 days. Following this ...
Biology Products: